

FREEDOM OF INFORMATION REQUEST

RF24-079

We can confirm East Kent Hospitals University NHS Foundation Trust (EKHUFT) holds the information you have requested. Please see our responses in bold text below.

1. How many patients did you treat with Bypassing agents (BPA)/Hemlibra inhibitor in Q4'23 (October, November, December 2023)?
 - a) With BPA/Hemlibra Inhibitor? <5
2. Please fill in the BPA/Hemlibra products *utilized* in October, November, and December 2023.

October 1st through December 2023		Q4'23 Volume (IU)/mg	Total Patients	Patients	
				Prophylaxis	On demand
	<i>Example: FEIBA</i>	50,000 IU	1	0	0
Hem A Inhibitor Patients					
Haem A Inhibitor Patients	FEIBA	0	0	0	0
	Cevenfacta	0	0	0	0
	NovoSeven	0	0	0	0
	Hemlibra	1,260	<5	<5	0
Haem B Inhibitor Patients	FEIBA	0	0	0	0
	Cevenfacta	0	0	0	0
	NovoSeven	0	0	0	0
	Obizur	0	0	0	0
AHA Patients					
AHA Patients	FEIBA	3,000	<5	0	<5
	NovoSeven	0	0	0	0
	Obizur	0	0	0	0
	Cevenfacta	0	0	0	0
	Hemlibra	0	0	0	0
Other Use					
FVII deficient	NovoSeven	0	0	0	0
Glanzmann's	NovoSeven	15,150	<5	0	<5
Other	NovoSeven	0	0	0	0
Other	Cevenfacta	0	0	0	0

3. How **many** minor and major surgeries did your BPA patients have in October, November, and December 2023?

	Inhibitor patients		Glanzmann, FVII deficiency, AHA	
	Minor surgeries	Major surgeries	Minor surgeries	Major surgeries
NovoSeven	0	0	0	0
FEIBA	0	0	0	0

Obizur	0	0	0	0
--------	---	---	---	---

4. How many minor and major surgeries did your BPA/Hemlibra inhibitor patients have in October, November, and December 2023?

	Inhibitor patients		Glanzmann, FVII deficiency, AHA	
	Minor surgeries	Major surgeries	Minor surgeries	Major surgeries
NovoSeven	0	0	0	0
FEIBA	0	0	0	0
Obizur	0	0	0	0

5. How many breakthrough bleeds did your Hemlibra Inhibitor patients have, and what brand were they treated with?

	Inhibitor patients	Q4'23 volume (IU/mg)
Hemlibra	0	0
NovoSeven	0	0
FEIBA	0	0

6. Were there any changes in the total number of acute bleeds treated with factor in Q4'23 as compared to Q3'23?

19 in Q3

26 in Q4

7. Was there any change in the number of elective surgeries **using factor** in Q4'23 as compared to Q3'23?

<i>Number of Surgeries</i>	<i>BPA</i>
Increase / Decrease / Stable compared to Q3'23?	Decrease
How many surgeries occurred in Q4'23?	4

8. Have any BPA patients switched products between October 1st through December 2023? What were the reasons for the switches? **No.**

Indication	Previous Medication	Previous Regimen	Current Medication	Current Regimen	Severity of patient	Reason
<i>Example: Haem B Inh.</i>	<i>1 NovoSeven</i>	<i>On- demand</i>	<i>Cevenfacta</i>	<i>Prophy 1x/week</i>	<i>Severe</i>	<i>Patient requested to try out a new product to improve treatment</i>

9. What is the total number of patients treated with NovoSeven at your Trust?

</=3

Please note that EKHUFT is unable to confirm the exact number where fewer than five patients are recorded. Given the low number, we consider that disclosure of such information, which constitutes personal data, would contravene the first data protection principle under GDPR. This states that personal data should be processed fairly and lawfully. It is the fairness aspect of this principle, which in our view, would be breached by disclosure. We believe that not disclosing this information is in line with Sections 40(2) and 40(3) of the Freedom of Information Act 2000.

(DATE OF RESPONSE: 19 FEBRUARY 2024)

